Equillium (EQ) 2024 Wells Fargo Healthcare Conference summary

Pipeline and business overview

• Two main business segments: itolizumab (partnered with Ono) and multi-cytokine programs acquired via Bioniz.

• Ono partnership includes an option to acquire itolizumab, with a decision due by October 30.

• EQ101, a lead multi-cytokine asset, targets IL-2, IL-9, and IL-15, with positive phase II data in alopecia areata.

• EQ302, an orally deliverable peptide targeting IL-15 and IL-21, is advancing toward first-in-human studies in 2025.

• Active business development efforts are ongoing to broaden the pipeline and explore monetization options.

Itolizumab partnership and development

• Ono paid $38M upfront and fully funds R&D through the option period, which ends October 30.

• Positive data delivered from lupus nephritis and GVHD studies; decision on acquisition will trigger a $35M payment and potential $100M+ in milestones.

• If Ono opts in, company will have strong cash position and continue pivotal studies toward BLA submission.

• If Ono declines, itolizumab returns unencumbered, with additional data from an ulcerative colitis study nearing completion.

• Either outcome is seen as favorable, with advanced-stage assets and manufacturing in place.

Multi-cytokine platform and clinical strategy

• EQ101 selectively inhibits IL-2, IL-9, and IL-15, aiming for efficacy with improved safety over JAK inhibitors.

• Phase II AA study showed efficacy comparable to low-dose JAK inhibitors, with plans to optimize dosing and switch to subcutaneous delivery.

• Targeting moderate to severe AA patients, addressing an unmet need for safer, chronic therapies.

• Market opportunity in AA estimated at $500M–$1B, with several hundred thousand eligible patients.

• EQ302 targets GI diseases like celiac and IBD, with preclinical data supporting dual cytokine inhibition; first-in-human studies planned for 2025.